CNS Neuroscience and Therapeutics

Aims & Scope

CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation.

The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Medline
• PubMed
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine and Pharmacology, Toxicology and Pharmaceutics, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 3,580.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Ketamine Pharmacology: An Update (<i>Pharmacodynamics and Molecular Aspects, Recent Findings</i>)

  Citation: 521

  Authors: Georges, Thierry

• Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment

  Citation: 465

  Authors: Mojtaba, Elham, Zahurin, Raymond, Norlinah, Abolhassan

• Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms

  Citation: 460

  Authors: Xiaowen, Basharat, Junlei

• Brain structure alterations in depression: Psychoradiological evidence

  Citation: 393

  Authors: Fei‐Fei, Wei, John A., Zhi‐Yun, Qi‐Yong

• REVIEW: Curcumin and Alzheimer's Disease

  Citation: 376

  Authors: Tsuyoshi, Kenjiro, Masahito

• The Pharmacology of Lysergic Acid Diethylamide: A Review

  Citation: 368

  Authors: Torsten, John H., Dirk O., Hinderk M., Annelie

• B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin

  Citation: 360

  Authors: Carlos Alberto, Mauricio Orlando

• Baicalin mitigates cognitive impairment and protects neurons from microglia‐mediated neuroinflammation via suppressing <scp>NLRP</scp>3 inflammasomes and <scp>TLR</scp>4/<scp>NF</scp>‐κB signaling pathway

  Citation: 326

  Authors: Xin, Ming‐Yan, Dong‐Fang, Xin, Ke, Ping, Wei‐Fan, Hua, Min‐Jie

• A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade?

  Citation: 320

  Authors: Mark C.

• Inhibition of ferroptosis attenuates tissue damage and improves long‐term outcomes after traumatic brain injury in mice

  Citation: 318

  Authors: Bao‐Shu, Yi‐Qin, Yong, Qing, Jun‐Feng, Guo‐Yi, Ji‐Yao